Blue Earth Diagnostics
Empowering the evolution of care for patients with cancer
Blue Earth Diagnostics is focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. The Company’s expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.
Blue Earth Therapeutics
Advancing next generation targeted radiopharmaceuticals to treat patients who have cancer
Blue Earth Therapeutics has exclusive worldwide rights to therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) radiopharmaceutical technology. The company has an emerging pipeline of precision targeted radiopharmaceuticals, initially focused on prostate cancer, with plans to expand into additional disease areas in oncology.
Blue Earth Therapeutics is leveraging its radiopharmaceutical development experience, as demonstrated by the rapid success of its sister company Blue Earth Diagnostics to advance its nuclear medicine portfolio and apply its expertise to the world of next-generation therapeutic radiopharmaceuticals.
Please fill out the form below and we will get back to you